The identification of tumor-expressed antigens that can be recognized by specific T
lymphocytes has made it possible both to study the properties of T cells participating in anti-
tumor immune responses in patients and also to develop antigen-specific immunotherapies
as a treatment modality. Interestingly, moves toward intervention have proceeded at a faster
pace than have investigations toward understanding. In melanoma in particular, many
clinical trials of active immunization have been performed, and many of these have shown …